泓博医药
(301230)
| 流通市值：64.20亿 | | | 总市值：71.38亿 |
| 流通股本：1.63亿 | | | 总股本：1.81亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 364,406,306.14 | 172,285,876.53 | 688,350,863.65 | 514,401,151.54 |
| 营业收入 | 364,406,306.14 | 172,285,876.53 | 688,350,863.65 | 514,401,151.54 |
| 二、营业总成本 | 348,643,419.8 | 159,696,084.51 | 655,923,295.42 | 484,120,946.96 |
| 营业成本 | 262,736,731.31 | 117,291,172.53 | 499,634,937.09 | 370,123,087.32 |
| 税金及附加 | 639,972.27 | 327,403 | 2,005,368.46 | 1,699,195.54 |
| 销售费用 | 7,363,927.4 | 3,128,969.66 | 13,569,256.13 | 9,760,944.88 |
| 管理费用 | 49,597,060.7 | 24,460,125.35 | 97,444,786.91 | 70,237,212.6 |
| 研发费用 | 20,906,941.98 | 10,743,761.5 | 37,148,768.17 | 28,793,189.61 |
| 财务费用 | 7,398,786.14 | 3,744,652.47 | 6,120,178.66 | 3,507,317.01 |
| 其中:利息费用 | 3,687,962.65 | 1,913,932.19 | 8,288,635.54 | 6,308,965.22 |
| 其中:利息收入 | 594,933.18 | 291,164.21 | 1,502,822.23 | 1,325,227.68 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 8,792,384.73 | 11,481,297.38 | 6,996,140.63 | 5,193,893.29 |
| 加:投资收益 | 11,631,711.8 | 6,807,055.73 | 105,380.53 | 105,380.53 |
| 资产处置收益 | - | - | 41,517.55 | - |
| 资产减值损失(新) | -8,429,343.94 | -5,434,496.52 | -11,886,307 | -3,049,235.81 |
| 信用减值损失(新) | -1,826,517.84 | 499,408.45 | -4,130,781.85 | -2,787,795.89 |
| 其他收益 | 5,540,488.56 | 455,561.28 | 5,067,576.86 | 2,274,911.81 |
| 四、营业利润 | 31,471,609.65 | 26,398,618.34 | 28,621,094.95 | 32,017,358.51 |
| 加:营业外收入 | 24,858.69 | 6,158.69 | 22,804.41 | 21,693.5 |
| 减:营业外支出 | 1,361,984.76 | 420,015.21 | 327,013.66 | 213,831.56 |
| 五、利润总额 | 30,134,483.58 | 25,984,761.82 | 28,316,885.7 | 31,825,220.45 |
| 减:所得税费用 | 1,405,119.84 | 2,205,512.32 | -5,977,881.62 | -2,924,358.81 |
| 六、净利润 | 28,729,363.74 | 23,779,249.5 | 34,294,767.32 | 34,749,579.26 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 28,729,363.74 | 23,779,249.5 | 34,294,767.32 | 34,749,579.26 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 28,729,363.74 | 23,779,249.5 | 34,294,767.32 | 34,749,579.26 |
| 扣除非经常损益后的净利润 | 6,460,341.64 | 6,456,551.86 | 23,245,061.23 | 27,709,531.17 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.16 | 0.17 | 0.25 | 0.25 |
| (二)稀释每股收益 | 0.16 | 0.17 | 0.24 | 0.25 |
| 八、其他综合收益 | -3,995.55 | -114,466.4 | -17,625.94 | -79,436.07 |
| 归属于母公司股东的其他综合收益 | -3,995.55 | -114,466.4 | -17,625.94 | -79,436.07 |
| 九、综合收益总额 | 28,725,368.19 | 23,664,783.1 | 34,277,141.38 | 34,670,143.19 |
| 归属于母公司股东的综合收益总额 | 28,725,368.19 | 23,664,783.1 | 34,277,141.38 | 34,670,143.19 |
| 公告日期 | 2026-08-28 | 2026-04-29 | 2026-04-29 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |